Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, F., Qiao, M. & Zhou, C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol. Immunol. 18, 279–293 (2021).

Article  CAS  PubMed  Google Scholar 

Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6, 38 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Khan, S. & Gerber, D. E. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin. Cancer Biol. 64, 93–101 (2020).

Article  CAS  PubMed  Google Scholar 

Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504–515 (2020).

Article  CAS  PubMed  Google Scholar 

Thapa, B. et al. Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI) [abstract]. J. Clin. Oncol. 37, e14151 (2019).

Article  Google Scholar 

Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).

Article  CAS  PubMed  Google Scholar 

Cook, S. et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw. Open. 7, e2352302 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Street, S. et al. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann. Oncol. 32, 1050–1051 (2021).

Article  CAS  PubMed  Google Scholar 

Haratani, K. et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4, 374–378 (2018).

Article  PubMed  Google Scholar 

Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F. & Eggermont, A. M. M. Clinical and translational attributes of immune-related adverse events. Nat. Cancer 5, 557–571 (2024).

Article  PubMed  Google Scholar 

Burke, K. P., Grebinoski, S., Sharpe, A. H. & Vignali, D. A. A. Understanding adverse events of immunotherapy: a mechanistic perspective. J. Exp. Med. 218, e20192179 (2021).

Article  CAS  PubMed  Google Scholar 

Singh, N., Hocking, A. M. & Buckner, J. H. Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity. Immunol. Rev. 318, 81–88 (2023).

Article  CAS  PubMed  Google Scholar 

Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073–4126 (2021).

Article  CAS  PubMed  Google Scholar 

Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217–1238 (2017).

Article  Google Scholar 

Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J. Immunother. Cancer 5, 95 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson, J. A. et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1. 2020. J. Natl Compr. Canc Netw. 18, 230–241 (2020).

Article  CAS  PubMed  Google Scholar 

Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706–3714 (2018).

Article  CAS  PubMed  Google Scholar 

Goodman, R. S., Johnson, D. B. & Balko, J. M. Corticosteroids and cancer immunotherapy. Clin. Cancer Res. 29, 2580–2587 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).

Article  PubMed  Google Scholar 

Mishra, S. P. et al. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut. Gut 72, 1848–1865 (2023).

Article  CAS  PubMed  Google Scholar 

Arifuzzaman, M. et al. Inulin fibre promotes microbiota-derived bile acids and type 2 inflammation. Nature 611, 578–584 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arima, K. et al. Western-style diet, pks Island-carrying Escherichia coli, and colorectal cancer: analyses from two large prospective cohort studies. Gastroenterology 163, 862–874 (2022).

Article  CAS  PubMed  Google Scholar 

Jiang, S. S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781–797.e9 (2023).

Article  CAS  PubMed  Google Scholar 

Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A. & Wargo, J. A. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33, 570–580 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804–1808 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu, M. et al. Gut microbiome for predicting immune checkpoint blockade-associated adverse events. Genome Med. 16, 16 (2024).

Article  CAS  PubMed  PubMed Central